Evaluation of the Symptomatic Treatment of Residual Neurological Symptoms in Wilson Disease by Hölscher, Sara et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Eur Neurol 2010;64:83–87  
 DOI: 10.1159/000316066 
Evaluation of the Symptomatic
Treatment of Residual Neurological 
Symptoms in Wilson Disease
 Sara Hölscher  a    Barbara Leinweber  a    Harald Hefter  b    Ulrike Reuner  c    
Peter Günther  d    Karl Heinz Weiss  e    Wolfgang H. Oertel  a    Jens Carsten Möller  a 
 a   Department of Neurology, Philipps University,  Marburg ,  b   Department of Neurology, Heinrich-Heine University, 
 Düsseldorf ,  c   Department of Neurology, Technical University,  Dresden ,  d   Department of Neurology, University Leipzig, 
 Leipzig , and  e   Department of Gastroenterology, Ruprecht-Karls University,  Heidelberg , Germany 
 Introduction 
 Wilson disease (WD) is an autosomal-recessive disor-
der of copper metabolism leading to excessive accumula-
tion of copper in several body organs and tissues affecting 
mainly the liver and/or the brain  [1–3] . The disease oc-
curs in about 1 of every 40,000 persons  [4] . The spectrum 
of possible clinical manifestations varies considerably. 
On the one hand, WD may present with hepatitis, chron-
ic cirrhosis, liver failure or just elevated serum transami-
nases  [2] . On the other hand, neurological symptoms, es-
pecially movement disorders caused by dysfunction of 
the basal ganglia and the cerebellum, are described  [5] . A 
psychiatric presentation including depression and chang-
es in behavior is also possible. Due to the rarity and
unspecific beginning of the disease, diagnosis is often
delayed  [4] . With early diagnosis and medical therapy, 
progress can be avoided in most cases, whereas without 
treatment the disease is usually lethal  [6] . However, de-
spite the removal of excess copper by chelating agents, 
WD patients can still feature residual neurological symp-
toms  [7] . To our knowledge, there are no data on the 
symptomatic treatment of WD patients with such symp-
toms and its potential effects.
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 Abstract 
 The intention of this analysis was to identify patients with 
treated Wilson disease (WD) and residual neurological symp-
toms in order to determine whether or not they were under-
going any treatment in addition to the common decopper-
ing medication. Moreover, the effects of any symptomatic 
medication were analyzed. Two samples of WD patients 
were investigated either by a mailed questionnaire survey
(n = 135) or by a retrospective analysis (n = 75). A consider-
able proportion of patients still suffered from neurological 
symptoms (n = 106, 50.5%), of whom a relatively small pro-
portion was treated symptomatically (n = 33, 31.1%). The 
documented effects varied substantially, with anticholiner-
gics and botulinum toxin (against dystonia) and primidone 
(against tremor) apparently being the most promising com-
pounds. Further studies are required to analyze the symp-
tomatic treatment of WD patients with residual neurological 
symptoms in more detail.  Copyright © 2010 S. Karger AG, Basel 
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 Patients and Methods 
 The study was approved by the Institutional Review Board of 
Philipps University and consisted of 2 parts.
 First, a questionnaire, a patient information leaflet and an in-
formed consent were mailed to the members of ‘Morbus Wilson 
e.V.’, the German self-support group. Patients who were interested 
to participate in this survey had to return the questionnaire along 
with the signed informed consent. A telephone number was pro-
vided in case of further inquiries. The questionnaire assessed the 
usual demographic data, the age of onset, presentation at disease 
onset and the current decoppering treatment. Symptoms at dis-
ease onset could be classified by the patient as neurological, he-
patic, psychiatric and other/none/unknown. Then, the current 
residual neurological symptoms were addressed. If any were re-
ported, the participants were requested to specify whether the 
symptoms could be assigned to 1 or several of the following sub-
groups: dystonia, parkinsonism and/or postural and action trem-
or. For this purpose, respective explanations and some space for 
a free text were provided. Subsequently, it was asked if the patient 
was currently or had previously been treated symptomatically. If 
so, the type and duration of treatment were to be recorded. Fi-
nally, the subjective efficacy of the treatment was rated on a scale 
from 0 to 4 (0 – no change, 1 – slight, 2 – moderate, 3 – good,
4 – very good improvement). Uncertainties in the questionnaire 
survey were clarified by telephone, if the patient had agreed
to be contacted. The questionnaire is provided in an English 
trans lation in the online supplementary material (see, www.
karger.com/doi/10.1159/000316066).
 Second, the files of WD patients from 5 specialized mainly 
neurological outpatient clinics in Germany were retrospectively 
analyzed using an identical data set.
 The obtained data were evaluated by descriptive statistics, us-
ing SPSS, version 15.0 for Windows.
 Results 
 A total of 210 WD patients were analyzed. One hun-
dred and thirty-seven of 270 contacted patients partici-
pated in the mailed questionnaire survey; 135 of these 
questionnaires could be evaluated. Additionally, the files 
of 87 patients were available, of whom 12 also participat-
ed in the mailed questionnaire survey. Accordingly, the 
remaining 75 patient files were used for the retrospective 
analysis. Sixty-one patients (45.2%) who participated in 
the mailed questionnaire survey subjectively reported the 
presence of neurological symptoms, whereas neurologi-
cal symptoms were identified in 45 patients (60%) of the 
retrospective analysis (i.e. 50.5% of the whole study pop-
ulation). The demographic and clinical characteristics
of both samples are presented in  table 1 . Both samples 
showed a similar sex distribution, mean age, age of onset 
and disease duration, distribution of symptoms at disease 
onset and decoppering therapy. Although our study was 
not designed to address this issue, we would like to men-
tion that fewer patients had residual neurological symp-
toms under a  D -penicillamine than under a trientine 
monotherapy (p = 0.008).
 Sixteen of 61 patients (26.2%) of the mailed question-
naire survey and 17 of 45 patients (37.7%) of the retro-
spective analysis (had) received symptomatic treatment 
(i.e. 31.1% of the whole study population). The assessment 
of subjective efficacy was not available in 3 patients of the 
mailed questionnaire survey (unknown medication, n = 
2; metixene and tiapride, n = 1), whereas no documenta-
tion of the effect was identified in 5 patients of the retro-
spective analysis (trihexyphenidyl, n = 3; biperiden, n = 
1; baclofen, n = 1).  Table 2 provides a summary of the used 
medications and their proposed effects in altogether 25 
patients. With respect to the mailed questionnaire sur-
vey, the classification of symptoms and their improve-
ment by therapy were primarily based on the self-assess-
ment of the patients. In cases where a medication was 
used in the presence of the usual target symptom, it was 
assumed that the reported efficacy was probably due to 
the administered compound. Apart from that, we did not 
consider it feasible to assign the effect of a given drug to 
a certain symptom merely based on a mailed question-
naire survey (and telephone interviews) or a retrospective 
analysis. Therefore, it was mentioned in  table  2 (‘com-
ments’) when a medication was administered in the ab-
sence of the usual target symptom. Furthermore, we in-
terpreted the assumed efficacy of a single compound in 
patients taking several drugs with increased caution (see 
 table 2 and Discussion).
 Discussion 
 In a previous report we already suggested that a sub-
stantial proportion of WD patients still features residual 
neurological symptoms  [7] . Furthermore, almost half of 
the patients taking part in the mailed questionnaire sur-
vey subjectively reported residual neurological symp-
toms. This estimate was corroborated by the results of the 
retrospective analysis where residual neurological symp-
toms were identified in 60% of the patients. This moder-
ately higher prevalence was probably due to a selection 
bias, since the retrospective analysis was performed 
among patients of specialized mainly neurological outpa-
tient clinics. However, the results from both investigated 
samples emphasize that residual neurological symptoms 
represent a frequent feature in WD patients despite a 
long-term decoppering therapy. Although not addressed 
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in the present study, this observation is compatible with 
a recent publication reporting a prevalence of psychiatric 
symptoms in up to 70% of treated WD patients  [8] .
 According to our knowledge, this study represents the 
first approach of how WD patients with residual neuro-
logical symptoms are symptomatically treated. The used 
medications covered a broad range of different drug 
classes reflecting the complex phenotype of patients with 
WD. Accordingly, anticholinergics and botulinum toxin 
as routine medications for dystonia,   -blockers and 
primidone as frequently used medications for tremor, 
and dopaminergic compounds as typical antiparkinso-
nian drugs were most frequently administered in our pa-
tients.
 Anticholinergics such as trihexyphenidyl (as mono-
therapy, n = 3) had a moderate to good effect in 2 patients 
and may hypothetically not only exert a beneficial effect 
on dystonia, but also on parkinsonism in patients with 
WD. Botulinum toxin (as monotherapy, n = 3) had a 
slight to good effect in these patients, which could be ex-
pected due to its peripheral mode of action in the treat-
ment of dystonia. Baclofen (as monotherapy, n = 1) had a 
good effect in this patient and may represent a possible 
treatment option in the treatment of dystonia in WD pa-
tients.
  -Blockers such as propranolol (as monotherapy, n = 
3) had a slight to good effect in these patients (however, 
in 2 patients with a combination therapy, no effect at all 
was reported). According to the results of this prelimi-
nary study, primidone (as monotherapy, n = 5) appears to 
be a more promising compound in the treatment of pos-
tural or action tremor in WD, since it had a moderate to 
very good effect in 4 patients reporting tremor.
 L -Dopa (as monotherapy, n = 1) did not have any effect 
in this patient. Since parkinsonism in WD patients is 
probably due to a lesion of both presynaptic (nigral) and 
postsynaptic (striatal) neurons, it could be discussed 
whether a dopaminergic therapy should only be initiated 
in WD patients with a normal (or only slightly patholog-
ical) dopamine receptor SPECT  [9] . Furthermore, apo-
morphine could be used to assess whether a given patient 
may respond to a dopaminergic therapy or not.
Table 1.  Demographic and clinical data
Questionnaire survey patients (n = 135) R etrospectively analyzed patients (n = 75)
n % mean SD min. max. n % mean SD min. max.
Sex
Female 86 63.7 45 60.0
Male 49 36.3 30 40.0
Mean age, years 40.9 (n = 134) 11.1 19 67 42.3 12.2 18 73
Mean age at onset, years 21.3 (n = 127) 9.3 4 46 19.7 (n = 61) 8.5 5 71
Duration of disease, years 19.8 (n = 127) 10.9 1 42 23.8 (n = 61) 12.8 2 53
Symptoms at disease onset
Neurological 42 31.1 25 33.3
Psychiatric 0 0.0 1 1.3
Hepatic 39 28.9 18 24.0
Others/none/not known 22 16.3 15 20.0
Neurological + psychiatric 4 3.0 5 6.7
Neurological + hepatic 16 11.9 6 8.0
Psychiatric + hepatic 3 2.2 0 0.0
Other combinations 9 6.6 5 6.7
Administration of
D-Penicillamine 57 42.2 35 46.6
Trientine 33 24.4 6 8.0
Zinc 29 21.5 17 22.6
D-Penicillamine + zinc 9 6.6 9 12.0
Trientine + zinc 7 5.2 5 6.6
Not known 0 0.0 3 4.0
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 The results with respect to tiapride (as monotherapy,
n = 3) are inconclusive since hyperkinesia is not a typical 
symptom in treated WD and was therefore not specifical-
ly addressed in the current study  [7] . However, it is worth 
mentioning that tetrabenazine (in combination therapy) 
had a good effect on hyperkinesia in 1 patient. Likewise, 
the treatment of hypersalivation in WD patients by botu-
linum toxin was not covered by the present investigation.
 Despite the large number of patients, this study has 
some methodological limitations since the results are de-
rived either from a survey using an unvalidated ques-
tionnaire or a retrospective analysis. Also, several pa-
tients received a combination therapy impeding the in-
terpretation of the obtained data with respect to the 
effect of a single compound. Therefore, these patients are 
shown in  table 2 , but were usually not included in the 
Table 2.  Effects of symptomatic treatment
Drug class Medication Subjective efficacy Symptoms Comments
Questionnaire
Anticholinergics trihexyphenidyl (n = 1) moderate (n = 1) parkinsonism, dystonia (n = 1)
BTX idem (n = 2) good (n  = 2) dystonia (n = 1);
parkinsonism, dystonia (n = 1)
-Blockers propranolol (n = 3) good (n = 1) tremor (n = 1)
moderate (n = 1) tremor, parkinsonism, dystonia (n = 1)
slight (n = 1) tremor (n = 1)
Barbiturates primidone (n = 1) moderate (n = 1) parkinsonism, dystonia (n = 1) no report of tremor
Dopaminergic compounds L-dopa (n = 1) none (n  = 1) parkinsonism (n = 1)
Dopamine antagonists tiapride (n = 2) good (n  = 1) tremor, parkinsonism, dystonia (n = 1) hyperkinesia not 
specifically addressed
none (n = 1) tremor, dystonia (n = 1)
Others n.a. n.a. n.a.
Several biperiden, BTX (n = 1) moderate (n = 1) parkinsonism, dystonia (n  = 1)
trihexyphenidyl, BTX, 
baclofen (n = 1)
moderate (n = 1) parkinsonism, dystonia (n = 1)
-blocker (unknown), 
primidone, L-dopa, 
clonazepam (n = 1)
none (n = 1) tremor, dystonia (n = 1) no report of parkinsonism
Retrospective analysis
Anticholinergics trihexyphenidyl (n = 2) good (n = 1) parkinsonism, dystonia (n = 1)
none (n = 1) parkinsonism, dystonia (n = 1)
BTX idem (n = 1) slight (n = 1) tremor, dystonia (n = 1)
-Blockers n.a. n.a. n.a.
Barbiturates primidone (n = 4) very good (n = 2) tremor, dystonia (n = 1), dystonia (n = 1)° ° probably initial tremor
good (n = 1) tremor, dystonia (n = 1)
moderate (n = 1) tremor, parkinsonism, dystonia (n = 1)
Dopaminergic compounds n.a. n.a. n.a.
Dopamine antagonists tiapride (n = 1) slight (n = 1) dystonia (n = 1) also hyperkinesia
Others baclofen (n = 1) good (n = 1) tremor, parkinsonism, dystonia (n = 1)
Several trihexyphenidyl, BTX, 
L-dopa (n = 1)
good (n = 1) parkinsonism, dystonia (n = 1)
BTX, tetrabenazine, 
ropinirole (n = 1)




amantadine (n = 1)
none (n = 1) tremor, dystonia (n = 1) no report of parkinsonism
B TX = Botulinum toxin; tremor = postural and action tremor; n.a. = not assessed.
 Symptomatic Therapy in Neurological 
WD 
Eur Neurol 2010;64:83–87 87
discussion. These limitations were mainly owed to the 
rarity of the disease. Nevertheless, we think that this is 
an important investigation, since it underlines that re-
sidual neurological symptoms are a frequent phenome-
non in treated WD and, for the first time, addresses their 
possible symptomatic treatment. Based on the available 
data, treatment with anticholinergics and botulinum 
toxin in WD patients with residual dystonia and with 
primidone in WD patients with persisting postural and 
action tremor, respectively, appears most promising. 
Prospective studies on the symptomatic treatment of re-
sidual neurological symptoms in treated WD are highly 
recommended.
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